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suggests that the iron
translocation site is at
the pore region of
ferroportin.
As the sole iron exporter in humans, ferroportin controls systemic iron homeostasis through
exporting iron into the blood plasma. The molecular mechanism of how ferroportin exports
iron under various physiological settings remains unclear. Here we found that purified
ferroportin incorporated into liposomes preferentially transports Fe21 and exhibits lower
affinities of transporting other divalent metal ions. The iron transport by ferroportin is
facilitated by downhill proton gradients at the same direction. Human ferroportin is also
capable of transporting protons, and this activity is tightly coupled to the iron transport.
Remarkably, ferroportin can conduct active transport uphill against the iron gradient, with
favorable charge potential providing the driving force. Targeted mutagenesis suggests that
the iron translocation site is located at the pore region of human ferroportin. Together, our
studies enhance the mechanistic understanding by which human ferroportin transports
iron and suggest that a combination of electrochemical gradients regulates iron export.
Introduction
Ferroportin is the only iron exporter known in vertebrates.1 At the systemic level, ferroportin exports iron
into the blood plasma from most cells involved in iron metabolism,2 including dietary iron absorbed by
duodenal enterocytes,3 stored iron released from hepatocytes,4 and the majority of body iron that is
recycled by macrophages through erythropoiesis. During pregnancy, ferroportin releases maternal iron
from placenta syncytiotrophoblasts into the fetal circulation.5 In addition to handling systemic iron flow,
ferroportin maintains local iron balance in heart and other tissues.6,7 Ferroportin has been proposed to
act as a “safety valve” that relieves cardiomyocytes8 from iron-overload conditions such as those caused
by thalassemia treatment.9-12 An important regulator of ferroportin is hepcidin,13-15 a peptide hormone
triggering the internalization and subsequent degradation of the iron exporter. This regulation represents
the most important control point of systemic iron homeostasis.2,8
Despite the physiological importance of ferroportin, the molecular mechanism of iron export remains
unclear. Ferroportin belongs to the major facilitator superfamily (MFS) of membrane transporters, most
of which use a cotransport mechanism, with proton being the typical coupling ion.16-19 The coupling
enables the proton cotransporters to overcome an unfavorable substrate gradient that can occur under
certain physiological conditions. The cotransport activity of ferroportin, however, is not obvious from
previous studies conducted in Xenopus oocytes,20,21 of which the intracellular pH cannot be controlled.
In addition, it is difficult to analyze metal efflux from cells20 because metal ions injected into the cells can
be sequestered by small chelator molecules or chaperone proteins. The cellular studies20,21 show that
ferroportin can transport Fe21, Co21, and Zn21 but disagree on whether ferroportin can transport Cd21
and Mn21.
To resolve these difficulties, the current study determined the transport activity of purified human
ferroportin in liposomes. Purified ferroportin actively transports Fe21 as in cells. Other divalent metal
ions, Co21, Ni21, and Mn21, are transported with decreasing affinities. Ferroportin can transport
protons, and this activity requires the cotransport of Fe21 (or Co21). Moreover, ferroportin can conduct
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uphill active transport against a Fe21 (or Co21) gradient. Mutagen-
esis analyses suggest that the iron translocation site is at the pore
region of ferroportin. Elucidation of the transport mechanism of
human ferroportin has implications for the control of iron export under
various physiological settings.
Methods
Cloning and protein purification
The coding sequence of human ferroportin was amplified with
polymerase chain reaction from an untagged clone (OriGene
SC127301) and subcloned into a modified pPICZ-B expression
vector (supplemental Figure 1A). A PreScission protease cleavage
site, enhanced green fluorescent protein sequence, and 103
histidine tag were added to the C-terminal of ferroportin. Ferroportin
mutants were generated by site-directed mutagenesis with the use
of QuikChange. The nucleotide sequences of all the constructs
were verified by DNA sequencing.
Wild-type and mutant ferroportin constructs were linearized and
transformed into Pichia pastoris. Zeocin-resistant colonies with the
highest expression level were inoculated to BMGmedia (1% glycerol,
0.34% yeast nitrogen base, 1% ammonium sulfate, 0.4 mg/mL biotin,
and 100 mM potassium phosphate, pH 6.0) and grown at 30°C for
20 hours. After an exchange to the media without glycerol, protein
expression was induced with 0.7% methanol for 2 days at 25°C. The
cells were harvested by centrifugation and flash-frozen in liquid
nitrogen.
For protein purification, 20 g frozen Pichia cells were applied to
a ball mill (Retsch) to break the cell wall. The cell membrane was
subsequently solubilized in a buffer containing 2% n-dodecyl
b-D-maltoside (DDM), 300 mM NaCl, 100 mM Tris-HCl, pH 8.0,
10 mg/mL DNase I, and protease inhibitors. After centrifugation, the
supernatant was incubated with Ni-NTA agarose, and the resin was
subsequently washed in a buffer containing 20 mM imidazole,
50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.2% DDM.
PreScission protease was added to remove the enhanced green
fluorescent protein and 103 histidine tag from ferroportin. After the
in-resin digestion, the protein was collected and concentrated for
the subsequent purification by size-exclusion chromatography
(Superdex 200). The peak fractions showing the highest UV
absorbance (supplemental Figure 1A) were pooled and concen-
trated to 20 mg/mL, and the fresh protein was immediately used for
liposome reconstitution.
Reconstitution of ferroportin into liposomes
The lipid mixture of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoe-
thanolamine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-
rac-glycerol) at a 3:1 ratio (wt/wt) was resuspended in the
reconstitution buffers used in different assays. The buffers contained
0.6% sodium cholate, and the final concentration of total lipids
was 10 mg/mL. The lipid suspension was sonicated and mixed
with purified ferroportin at 1:40 protein-to-lipid ratio (wt/wt). Bio-
beads were added to remove the DDM detergent and to promote
the liposomal reconstitution of ferroportin. After 2 hours, the
protein concentration of the supernatant containing proteolipo-
somes was measured with a bicinchoninic acid assay and
adjusted to the same protein concentration for wild-type and
mutant ferroportins. The proteoliposomes were stored on ice
before the transport assays.
Transport assay of divalent metal ions
The reconstitution buffer used for the metal transport assay
contained 150 mM NaCl and 25 mM of different pH buffers, which
are MES-NaOH pH 6.0, MES-NaOH pH 6.5, HEPES-NaOH pH
7.0, HEPES-NaOH pH 7.5, and Tris-HCl pH 8.0. These pH buffers
and the buffers containing 5 mM CaCl2 were used during the lipid
resuspension and ferroportin reconstitution. After the reconstitution,
the proteoliposomes were mixed 1:1 (vol/vol) with the reconstitution
buffers containing 500 mM calcein. Calcein was enclosed into the
proteoliposomes through 3 freeze-thaw cycles and sonication. The
proteoliposomes were subsequently passed through aG50 desalting
column to remove free calcein and to exchange the buffers outside of
the liposomes.
The metal transport assay was performed in 96-well plates with
a Synergy 2 plate reader (BioTek), and the calcein fluorescence
was detected with the excitation wavelength at 494 nm and
emission at 516 nm. After 5 minutes equilibration, 10 mM FeCl2,
100 mM CoCl2, 100 mM MnCl2, or 100 mM NiCl2 was added. For
the competition assay, 100 mM of ZnCl2, CdCl2, CaCl2, or MgCl2
was added together with 10 mM FeCl2. The metal transport through
ferroportin was monitored for another 20 minutes. At 25 minutes,
1 mM calcimycin was added to allow metal influx through this
ionophore. The intensity of the calcein fluorescence at 25 minutes
was expressed as a percentage of the fluorescence before the
metal ions were added (between 0 and 5 minutes), and this was
used as a measure of transport activity.
Proton transport assay
The proteoliposomes were enclosed with a reconstitution buffer
containing 150 mM KCl and 25 mM HEPES-KOH pH 7.5.
Subsequently, the proteoliposomes were flowed through a G50
column prewashed with 150 mM NaCl and 25 mM HEPES pH 7.5.
For the analysis of proton uptake, the same buffer with 1 mM 9-
amino-6-chloro-2-methoxyacridine (ACMA) was added at the
outside of the liposome; ACMA can diffuse freely into the liposomes
but cannot diffuse out once it is proton bound.22 The ACMA
fluorescence was detected with an excitation wavelength at 410 nm
and emission at 490 nm. After 5 minutes of equilibration, 10 mM
FeCl2 (or 20 mM CoCl2) and 20 nM valinomycin were added to
generate an electrochemical gradient. The proton transport through
ferroportin was monitored for another 20 minutes. At 25 minutes,
1 mM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) was
added to allow proton influx through this proton channel. The
intensity of the ACMA fluorescence at 25 minutes was expressed
as a percentage of the fluorescence before the metal ions were
added (between 0 and 5 minutes), and this was used as a measure
of proton transport activity.
Assay of active transport against the
Fe21/Co21 concentration gradient
For the analysis of active transport, the reconstitution buffer
enclosed in proteoliposomes was 25 mM HEPES pH 7.5,
150 mM KCl, 100 mM FeCl2 (supplemented with 100 mM sodium
ascorbate to prevent oxidation), or 100 mM CoCl2. The proteoli-
posomes were quickly flowed through a G50 spin column and
immediately used for the transport assay. To measure proton
transport, a buffer containing 25 mMHEPES pH 7.5, 150 mMNaCl,
and 1 mM ACMA was added from the outside of the liposome.

















L user on 27 O
ctober 2020
After 5 minutes equilibration, 1 mM FeCl2 (with 1 mM sodium
ascorbate) or 1 mM CoCl2 and 20 nM valinomycin were added.
The proton transport through ferroportin was monitored for
another 20 minutes. At 25 minutes, 1 mM CCCP was added to
allow proton influx through this proton channel.
Results
Purified human ferroportin in a liposomal system
transports iron efficiently
To conduct the transport assay in proteoliposomes, we expressed
human ferroportin in P pastoris and purified the protein (supple-
mental Figure 1). During the purification, the wild-type protein (and
mutant proteins used in later experiments) showed one major peak
on size-exclusion chromatography. The wild-type ferroportin was
reconstituted into liposomes, which was subsequently enclosed
with calcein, a fluorophore that specifically binds divalent ions
(Figure 1A). Fe21 and other divalent metal ions (M21) were
provided from the outside of the liposomes to generate an influx
gradient, and metal ions transported into the liposomes were
detected by the quenching of calcein fluorescence.23,24
The reconstituted ferroportin shows a large activity of Fe21
transport (Figure 1B). At high Fe21 concentrations (1.2-5 mM),
the calcein fluorescence is quenched to ;50% to 60%. As
a control, calcimycin, a divalent cation ionophore, was added later
to allow untransported Fe21 to cross liposome membranes. In the
presence of calcimycin, the fluorescence is lowered by another
;40%. In contrast, the empty liposome without ferroportin
incorporated shows little decrease of fluorescence (;10%),
whereas adding calcimycin lowers the fluorescence by another
;80%. Taken together, ferroportin can transport a large fraction of
iron provided to the liposomal system.
To further validate the liposomal assay of ferroportin activity, we
showed that the Fe21 transport mediated by ferroportin follows
Michaelis-Menten kinetics (Figure 1C). The Fe21 influx is saturated
at moderate to high Fe21 concentrations. If Fe21 had entered the
proteoliposomes by significant leakage, the apparent influx would
have increased proportionally with the Fe21 gradient. Instead, this
saturability is due to the limit imposed by ferroportin transport, and
the Fe21 influx is primarily through ferroportin. The apparent
Michaelis constant (KM) of Fe
21 is 0.077 mM, close to the apparent
affinity constant (#0.1 mM) estimated from a cellular assay20; this
consistency indicates that the reconstituted ferroportin has a similar
activity as in the cellular environment and that the liposomal assay
can mimic physiological conditions.
Human ferroportin preferentially transports iron over
other divalent metal ions
We tested the transport of other divalent metal ions by ferroportin
(Figure 2A-B) to compare with the cellular studies.20,21 The
apparent KM for Co
21 transport is 5.2 mM, consistent with the
apparent affinity constant of #5 mM from the cellular assay.20
Ferroportin can also transport Ni21 (KM 5 12.7 mM) in vitro; this
Ni21 transport activity has not been directly shown before.21
Ferroportin is a poor transporter of Mn21, with a KM of 40 mM and
a lower Vmax (maximum rate of transport) compared with other
metals. This apparent KM of Mn
21 is lower than that observed in
cellular assays (;740 mM), probably because most Mn21 is
sequestered in cells and free Mn21 is at a low concentration. The
KM of Mn
21 is nevertheless high, supporting the assertion that
Mn21 is unlikely a physiological substrate of ferroportin. It remains
possible, however, that ferroportin may slowly detoxify Mn21 given
a prolonged period of time. Our in vitro assay cannot analyze the
activity of Cu21 because it causes a precipitation of the proteolipo-
some. In addition, Ca21, Mg21, Cd21, and Zn21 do not quench
calcein fluorescence. To overcome this problem, we analyzed the
competition23 of these ions against Fe21 transport (Figure 2C).
Ca21 and Mg21 at 100 mM do not affect Fe21 transport. In
contrast, 100 mM Cd21 and Zn21 can inhibit the transport of Fe21
(10 mM), suggesting that ferroportin may be able to transport Cd21
and Zn21. Taken together, it is clear that ferroportin can transport
several divalent transition-metal ions in addition to Fe21. Given that
C
[Fe2+] (µM)
KM = 77 ± 10 nM
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Figure 1. Purified human ferroportin (FPN) actively transports iron into liposomes. (A) Fluorescence-based assay of Fe21 transport by FPN. The chemical gradient of
Fe21 drives the Fe21 transport by FPN into the liposome. The Fe21 influx is detected by the quenching of calcein fluorescence enclosed in the liposome. (B) Time-resolved
FPN transport of Fe21. The representative curves show the fluorescence quenching at different Fe21 concentrations. Addition of Fe21 and calcimycin (Cal) are indicated
above the curves. The FPN-mediated Fe21 transport is between 5 and 25 minutes and is saturated at high Fe21 concentrations. Empty liposomes and FPN-containing
liposomes with 0 mM Fe21 are used as controls. (C) Michaelis-Menten curve of Fe21 transport. The error bar of each data point is from duplicated experiments. Error of the
apparent KM is calculated from the curve fitting of the duplicates by GraphPad Prism.
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Co21 is more resistant to oxidation, we included Co21 in subsequent
experiments to compare with Fe21 transport. The apparent KM of
Fe21 is much lower than that of Co21, Ni21, and Mn21, indicating
that ferroportin preferentially exports Fe21 over other divalent
metal ions.
Proton gradients facilitate the iron transport by
ferroportin at the same direction
With the liposomal transport assay established, we investigated
whether the iron transport of human ferroportin can be altered by
proton gradients (Figure 3A). We first tested the pH profile of iron
transport activity in the absence of a proton gradient. With the same
pH maintained at the inside and outside of proteoliposomes, we
found that ferroportin is maximally active at pH 7.5 but loses most of
its Fe21 or Co21 transport activity at pH 6 and pH 8 (Figure 3B-C),
consistent with previous cellular assays.20 To generate proton
gradients, we kept pH 7 at one side of the liposomes and varied the
pH at the other side. With the pH gradients, the most notable
change in the pH profiles is that the maximum activity of Fe21 or
Co21 transport is now observed at pH 8 inside, when pH 7 is
provided at the outside (pH 8in/7out) (Figure 3B-C). When pH 7 is
provided at the inside, a notable difference is that 7in/6out shows
a higher activity than pH 6in/6out and pH 6in/7out. The complicated
changes in the activity levels reflect combined effects from the
proton gradients, the intrinsic pH profile of ferroportin, and the
unidirectional Fe21 or Co21 gradient being applied to the system.
When larger proton gradients were applied (Figure 3D-E), the
highest Fe21 or Co21 transport activity is observed with pH 8in/6out.
Taken together, the inward transport of Fe21 (or Co21) by
ferroportin can be stimulated by the inward proton gradient across
the membrane.
Apart from the proton gradient, a recent report found that
extracellular Ca21 stimulates ferroportin activity in cells.25 With
the purified system, here we show that Ca21 inside the liposome
enhances the Fe21 transport activity of ferroportin (Figure 3F),
consistent with the cellular assays. In contrast, Ca21 at the
outside has no stimulatory effect. Thus, Ca21 needs to be present
at the side toward which ferroportin transports Fe21; this
directionality is conceptually the same as observed with cellular
assays, in which iron export requires extracellular Ca21. Because
Ca21 and proton gradient both enhance Fe21 transport, we
investigated the relationship between these 2 stimulators. We
found that the transport activity increases by approximately
fourfold with pH 8in/6out, and increases by sixfold with 5 mM Ca
21
at pH 8in/8out. When 5 mMCa
21 and pH 8in/6out are both applied,
the activity increases cumulatively to 10-fold. This observation
suggests that the extracellular Ca21 and proton gradient may act
together to enhance (or regulate) ferroportin activity under
physiological conditions.
Ferroportin is a proton symporter
To detect whether ferroportin can transport proton, we used an
ACMA fluorophore to follow the change of proton concentration in
proteoliposomes22 (Figure 4A). To allow sufficient pH change
detectable by the quenching of ACMA, we need to neutralize the
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Figure 2. Human ferroportin preferably transports Fe21 over other divalent metal ions. (A) Transport activity of Co21, Ni21, and Mn21 using the calcein-based assay
(as in Figure 1). Addition of these divalent metal ions is indicated above the curves. All metal ions are provided at the concentration of 100 mM. (B) Comparison of the
apparent KM of ferroportin-mediated transport of different metal ions, with the y-axis break at 0.1 mM. (C) Competition of other divalent ions (Zn
21, Cd21, Ca21, and Mg21)
against Fe21 transport. Fe21 and the competing metal ions are provided at the concentrations of 10 mM and 100 mM, respectively.
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Figure 3. Proton gradients facilitate Fe
21
and
Co21 transport in the same direction. (A) Assay
of the Fe21 transport activity (same as in Figure 1)
with the variations of pH inside and outside the
liposome. (B) Comparison of the pH profiles of Fe21
transport with and without proton gradients. The same
pHs inside and outside the liposomes (green curve)
show the pH dependence of ferroportin (FPN) activity
without a proton gradient. The proton gradients
across the membrane are generated by keeping pH 7
at inside (blue curve) or outside (red curve) the
liposomes and varying the pHs at the other side. Fe21
is provided at 10 mM concentration. (C) Comparison
of the pH profiles of Co21 transport with and without
proton gradients. Co21 is provided at 100 mM
concentration. (D-E) Relative Fe21 and Co21 trans-
port activities with proton gradients between pH 6
and pH 8. All error bars are standard deviations from
3 repeats. (F) Fe21 transport activities with 5 mM
Ca21 inside and/or outside the liposomes. (G) Fe21
transport activities with 5 mM Ca21 inside and with
proton gradients between pH 6 and pH 8.
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that prevent further influx. We therefore loaded liposome with KCl
inside and an equal concentration of NaCl outside, and added
valinomycin, a K1 ionophore, to allow selective outflow of K1,
thereby generating counteractive negative charges inside the
liposome.
In the presence of ferroportin, significant proton influx is observed
when the Fe21 or Co21 gradient and the negative charge potential
are applied together (Figure 4B-C). In contrast, the charge potential
alone does not promote much proton inflow. The Fe21/Co21
gradient alone only promotes low proton inflow due to the
accumulation of positive charges. As a control, CCCP, a proton
channel, was added later to allow further proton influx, and the
relative levels of fluorescence quenching confirm that the proton
influx mediated by ferroportin is significant. Taken together,
ferroportin is capable of transporting protons, and the proton
transport requires the presence of Fe21/Co21. The downhill
Fe21/Co21 gradient used here should also promote the Fe21/Co21
transport (Figure 1). Because the Fe21 and H1 are cotransported in
the same direction, ferroportin is an Fe21/H1 symporter.
Ferroportin mediates secondary active transport
Proton symporters should support secondary active transport.26-28
Therefore, in principle, a favorable electrochemical potential will
drive ferroportin to move Fe21 or Co21 uphill against its concen-
tration gradient. To demonstrate this active transport, we set the
Fe21/Co21 concentrations at 1 mM outside the proteoliposomes
and 100 mM inside (Figure 5A). The uphill influx was driven by
a negative-inside charge potential, generated from selective K1
efflux as explained earlier. Direct analysis of the Fe21/Co21
transport activity is, however, infeasible because the calcein
fluorophore binds the metal ions and lowers their concentra-
tion inside the liposome to an unknown level. Thus, we
analyzed proton transport instead.23 A large proton influx, which
was driven by the charge potential, was observed against
the uphill Fe21/Co21 gradient (Figure 5B-C). Remarkably, if
Fe21/Co21 was not provided from the outside, the proton
transport did not occur, indicating that the proton transport is
tightly coupled to the Fe21/Co21 transport. Because of this
coupling, the proton transport indicates the uphill transport of
Fe21/Co21 against their chemical gradients. Taken together,
these data show that the symport of Fe21/Co21 and proton can
be driven uphill against the chemical gradient of Fe21/Co21.
Mutations disrupting the iron and proton transport
activities of ferroportin
To understand the structural basis of iron export, we built homology
models29 of human ferroportin (Figure 6A) based on the crystal
structures of a bacterial homolog.24 The bacterial structures were
determined at the inward- and outward-facing conformations, which
allow alternating access during the substrate transport, a mecha-
nism believed to be used by all MFS transporters.16 In this bacterial
homolog, the iron-binding site is located at the N-half of the protein
(N-lobe) and buried in the transmembrane helices. The iron is
coordinated by 4 residues (T20, D24, N196, and S199) in the
crystal structures of the bacterial homolog; in human ferroportin, the
corresponding residues constituting this putative iron-bind site are
S35, D39, N212, and S215, respectively. Biochemical analyses of
the bacterial homolog show that the D24A mutant has drastically
reduced transport activity.24 In addition, the iron-binding affinity is
lowered by several folds with D24A, N196A, and D24A/N196A
mutations.
We mutated D39 and N212 in human ferroportin to determine
whether it shares the same iron-binding site as the bacterial
homolog. Surprisingly, we found that mutations of D39A, N212A,
D39A/N212A, and H32A, a nearby residue (Figure 6A), all retain
a similar activity of iron transport as the wild-type human ferroportin
(supplemental Figure 2A). Moreover, the apparent KM values of
D39A, N212A, D39A/N212A, and H32A are similar or even better
than that of the wild-type ferroportin (supplemental Figure 2B).






















FPN + Val + Fe2+
Empty + Val + Fe2+
Time (min)
0%



















FPN + Val + Co2+
Empty + Val + Co2+
Time (min)
0%






Figure 4. Human ferroportin (FPN) transports proton along the iron gradient. (A) Assay of proton transport based on the quenching of ACMA fluorescence. ACMA
is provided from the outside to diffuse into the liposome22 (black arrow). After proton is bound, ACMA cannot diffuse out. To promote proton transport by FPN, 10 mM Fe21
is provided at the outside to generate an influx gradient. The positive charge (blue sphere) introduced by Fe21 and H1 influx is compensated for by K1 outflow through
valinomycin (blue arrow). (B) Proton transport by FPN requires a Fe21 gradient. Addition of Fe21 at 5 minutes and CCCP at 25 minutes are indicated above the curves, and
valinomycin (Val) is added at 0 minutes. (C) Proton transport by FPN in the presence of a Co21 gradient. To generate an influx gradient, 100 mM Co21 is provided from the
outside of the liposome. Other experimental setups are the same as in panel B.
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iron-transport activities and the apparent KM, these ineffective
mutations suggest that the iron-binding site of human ferroportin is
different from that of the bacterial homolog.
The N-lobe location of the iron-binding site in the bacterial homolog is
known to be unusual (Figure 6A) because all other MFS transporters
with known structures bind substrates at the interface between the
N- and C-lobes.16 The homology models of human ferroportin show
several acidic and histidine residues around this interface region,
including H32, D39, D181, E219, D254, D325, D473, E486, D504,
and H507; these residues are capable of binding iron or protonate
under a physiological pH. We therefore mutated all of these
candidate residues to identify those involved in proton and iron
transport. Among the 12 mutants tested, only D181N exhibits low
Fe21 or Co21 transport activity, suggesting that D181 is involved
in the iron binding (Figure 6B-C). In addition, D181N has a low
proton transport activity compared with the wild-type ferroportin
(Figure 6D-E). The homology models show that D181 can be
alternatively accessed at the inward- and outward-facing con-
formations, supporting that D181 constitutes part of the iron-
translocation pore.
Unlike D181N, several other mutants can actively transport Fe21
/Co21 but exhibit low activities of transporting proton, indicating
that these 2 activities can be decoupled (Figure 6D-E). The E219A
and E486A mutants both can decouple the proton-iron symport.
E219Q, however, is active for both Fe21/Co21 and proton
transport, whereas E486Q mutant decouples the symport; these
mutations were tested because the glutamine side chain cannot
be protonated. D254N drastically lowers the proton transport
activity, whereas D39N, D325N, and D473N exhibit ;50% to
60% of activity compared with the wild-type ferroportin. In
contrast, H32A, D504N, and H507A remain largely active for iron
and proton transport. These residues are unlikely to be involved in
the transport process. Taken together, decoupling of iron and
proton transport activities is probably because the mutations
disrupt the protonation or deprotonation process during the
ferroportin-mediated transport.
Discussion
In this study, we established a liposomal assay to analyze the transport
activities of purified human ferroportin. This proteoliposome system
enables the precise characterization of transport activities of human
ferroportin and avoids limitations of cell-based assays (Figure 1). For
example, it is difficult to measure proton transport or to control the
concentration of free iron in cells. Compared with iron export from cells,
the iron import into the proteoliposomes is in a reversed direction but is
conceptually equivalent. Ferroportin can transport iron into liposomes
with an apparent KM at the submicromolar range, consistent with the
cell-based assays. This low KM allows ferroportin to efficiently transport
iron even at low cellular concentrations.
Ferroportin shows considerable activity of transporting several
other transition metal ions, suggesting that ferroportin may also
export these metals from various cells. The exporter activity of
ferroportin is unusual among the numerous metal transporters
found in cells, most of which are importers of metal ions.30 Thus, this
unusual exporter may be used in vivo for protection against the
cytotoxicity caused by overload of transition metal ions. Compared
with Fe21 transport, however, ferroportin exhibits a much larger KM
of transporting other transition metals (Figure 2B). Thus, it is
possible that ferroportin does not affect the normal metabolism of
these metals but acts as a safety valve when these metal ions
exceed certain cellular levels. Furthermore, overloaded iron and
other transition metals are known to induce ferroportin expression in
various cells, such as macrophages.31-36 This regulatory mecha-
nism may serve as another trigger for ferroportin to export these
transition metals and detoxify cells.
Ferroportin exhibits tightly coupled activities of proton and iron
transport at the same direction (Figure 4B-C). The mechanism of
proton symport is most well studied in LacY, a canonical MFS
transporter.26 Protonation of LacY is required for substrate binding,
which induces the transition between the inward- and outward-
facing conformations. This structural transition allows substrate
release, which is associated with side chain rearrangements that
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Figure 5. Human ferroportin (FPN) supports uphill active transport. (A) Assay of proton transport with an uphill Fe21 gradient. The gradient is generated by enclosing
100 mM Fe21 inside the liposome and providing 1 mM Fe21 from the outside. The influx of Fe21 and H1 is promoted by a charge gradient that is generated from the K1
outflow through valinomycin (Val; blue arrow). The assay of proton transport by the quenching of ACMA fluorescence is the same in Figure 4. (B) FPN transports protons
against an uphill Fe21 gradient. Addition of Fe21 and CCCP are indicated above the curves. (C) FPN transports protons against an uphill Co21 gradient, with 100 mM Co21
enclosed inside the liposome and 1 mM Co21 provided from the outside.






















































































































































































































































































Figure 6. Iron and proton transport activities of ferroportin mutants. (A) Homology model of human ferroportin in inward-open (left) and outward-open (right) con-
formations. The models are generated by I-TASSER45 using the PDB code 5AYN and 5AYO. The iron-binding site in the bacterial homolog is shown in cyan sphere. (B-C)
Relative Fe21 and Co21 transport activities of mutants. Experimental setups are the same as in Figure 1. (D-E) Relative proton transport activities of the mutants under a
Fe21 and Co21 gradient. Experimental setups are the same as in Figure 4.
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LacY, the tight coupling between proton and iron transport can also
be explained. By analogy, iron binding at the inward-facing
conformation is required to induce the structural transition to the
outward-facing conformation to release iron. In the absence of the
iron binding and release, the proton transport, which involves
protonation and deprotonation at the alterative conformations,
becomes insignificant (Figure 5B-C).
Ferroportin uses multiple mechanisms to enhance its transporter
activity. Inspired by a previous report,25 here we found that the
presence of Ca21 increases ferroportin activity in the purified
liposomal system (Figure 3F). Because Ca21 and proton gradient
enhance the ferroportin activity cumulatively (Figure 3G), they seem
to use different mechanisms, presumably through modulating the
protein conformation in different ways; if a similar mechanism were
used, Ca21 and proton gradient should have overcome the need of
each other for enhancing the activity. Moreover, iron export into the
blood plasma is facilitated by ferroxidases8 such as ceruloplasmin
and hephaestin, which oxidize Fe21 to Fe31.
Among the mutants of 11 acidic or histidine residues we tested,
D181N is the only one inactive for both iron and proton transport
(Figure 6B-E). The homology models of human ferroportin
show that D181 is located at the interface between the N- and
C-lobes, a location consistent with that of the translocation pore
(Figure 6A). If the iron binding is disrupted by D181N, the
structural transition cannot be induced to allow proton transport,
consistent with the loss of both activities. Clinically, a D181V
mutation leads to ferroportin disease, suggesting the importance
of this residue in the function of iron export.37 Moreover, the
region around D181 on TM5 is a hotspot of ferroportin disease
mutations, including N174I, R178Q, I180T, Q182H, and N185D/
T.38-40 The cluster of these mutations also suggests that the
translocation site is located around D181. Taken together, the
iron translocation by human ferroportin probably involves D181,
and this translocation site is at the pore region, similar to other
MFS transporters.
This pore location of iron binding and translocation site is different
from that reported in the bacterial homolog.24 Due to the
considerable sequence similarity, the overall structures of human
ferroportin should be largely similar to the crystal structures of the
bacterial homolog, which has revealed an unusual iron-binding site
at the N-lobe of the bacterial protein. However, human ferroportin
mutants at this site can transport iron with similar Vmax and KM as the
wild-type protein, unlike the corresponding mutants of the bacterial
homolog. Thus, our data indicate key differences between the
human ferroportin and its bacterial homolog, the latter of which is
also not a proton symporter.
Several mutations can decouple the proton transport from iron
transport. For instance, the E486Q mutant mimics the protonated
form of E486, allowing ferroportin to bind iron with high affinity
and to conduct iron transport, but this mutant cannot transport
proton (Figure 6B-E). The homolog model at the outward-facing
conformation shows that E486 is at the C-lobe of ferroportin and
forms a salt bridge with R88 at the N-lobe. At the inward-facing
conformation, however, these residues are far apart, thereby
allowing the protonation of E486. However, E486 is located at
the intracellular surface and not exposed to the extracellular side at
the outward-facing conformation (Figure 6A). Because E486
cannot be deprotonated at the outward-facing conformation, the
proton transport cannot be mediated by E486 alone. Instead,
this residue probably serves as the initial proton-binding site on
a translocation path, whereas the actual residues mediating the
proton transport remain to be identified. Similar to LacY, protonation
of ferroportin may increase its affinity of iron binding; in LacY, the
protonation is on a glutamate residue, which does not bind the
substrate directly but donates the proton to assist substrate
binding.41 Overall, the structural mechanism of proton-symport in
ferroportin remains to be answered.
Proton coupling is broadly used by MFS transporters as the
energy source to conduct active transport.16 The efficiency of
iron export is determined by the iron and proton gradient.
Membrane potential also contributes to the overall electro-
chemical gradient because ferroportin is an electrogenic
symporter of Fe21 and H1. The negative charge potential inside
cells is against the export of the positively charged Fe21 and H1.
Theoretically, for the Fe21 export to occur, the regular membrane
potential of 260 mV requires a 1000-fold concentration gradient
of Fe21 across the plasma membrane (assuming one proton
cotransports with one Fe21). To overcome this unfavorable
and potentially controlling barrier of membrane potential, one
plausible solution is to coordinate iron export with iron import in
various cell types. In duodenal enterocytes, iron41-43 and many
other nutrients are imported through various proton symporters8
(supplemental Figure 3A). In macrophages, iron released in the
phagolysosome is also transported to cytoplasm by proton
symporters, DMT118 and Nramp1 (supplemental Figure 3B).
These protons, together with the imported iron, may gener-
ate sufficient driving force for iron export. As an exception,
cardiomyocytes constantly depolarize to generate a reversed
membrane potential, which may facilitate iron export and protect
these cells against iron overdose44 (supplemental Figure 3C).
Examining these hypotheses under physiological or cellular
conditions will shed light on the control and driving force of iron
export in vivo.
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